Cellectis S.A. Company Profile (NASDAQ:CLLS)

About Cellectis S.A. (NASDAQ:CLLS)

Cellectis S.A. logoCellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CLLS
  • CUSIP: N/A
  • Web: www.cellectis.com
Capitalization:
  • Market Cap: $987.74 million
  • Outstanding Shares: 35,862,000
Average Prices:
  • 50 Day Moving Avg: $27.89
  • 200 Day Moving Avg: $27.89
  • 52 Week Range: $16.09 - $30.46
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.42
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $49.26 million
  • Price / Sales: 20.33
  • Book Value: $7.81 per share
  • Price / Book: 3.57
Profitability:
  • EBIDTA: ($78,280,000.00)
  • Net Margins: -164.32%
  • Return on Equity: -26.70%
  • Return on Assets: -22.02%
Debt:
  • Current Ratio: 5.46%
  • Quick Ratio: 5.46%
Misc:
  • Average Volume: 187,243 shs.
  • Beta: 2.31
  • Short Ratio: 3.64
 

Frequently Asked Questions for Cellectis S.A. (NASDAQ:CLLS)

What is Cellectis S.A.'s stock symbol?

Cellectis S.A. trades on the NASDAQ under the ticker symbol "CLLS."

How were Cellectis S.A.'s earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) posted its quarterly earnings data on Monday, November, 16th. The company reported ($0.40) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.43) by $0.03. The company had revenue of $11.10 million for the quarter, compared to analyst estimates of $1.23 million. Cellectis S.A. had a negative net margin of 164.32% and a negative return on equity of 26.70%. View Cellectis S.A.'s Earnings History.

When will Cellectis S.A. make its next earnings announcement?

Cellectis S.A. is scheduled to release their next quarterly earnings announcement on Tuesday, November, 28th 2017. View Earnings Estimates for Cellectis S.A..

Where is Cellectis S.A.'s stock going? Where will Cellectis S.A.'s stock price be in 2017?

7 equities research analysts have issued 1-year price objectives for Cellectis S.A.'s stock. Their predictions range from $20.00 to $49.00. On average, they anticipate Cellectis S.A.'s stock price to reach $40.00 in the next twelve months. View Analyst Ratings for Cellectis S.A..

What are analysts saying about Cellectis S.A. stock?

Here are some recent quotes from research analysts about Cellectis S.A. stock:

  • 1. According to Zacks Investment Research, "Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. " (8/10/2017)
  • 2. Instinet analysts commented, "Cellectis is a leader in gene-editing and autologous CAR-T therapy. Recently presented clinical data for UCART19 established proof-of-concept (POC) for a safe off-the-shelf CAR-T (UCART) therapy. We believe that this POC enables rapid development of novel UCART therapeutics and that next-generation treatment protocols and gene-edits entering clinical testing in 2017 will allow for next UCART therapies to enter trials in rapid succession, driving upside in the shares over the next 12 months. We also view the shares as attractively priced, given that CLLS, a clinical-stage biotech, trades at a discount to preclinical gene-editing and clinical-stage CAR-T peers." (3/1/2017)

Who are some of Cellectis S.A.'s key competitors?

Who are Cellectis S.A.'s key executives?

Cellectis S.A.'s management team includes the folowing people:

  • Andre Choulika, Chairman of the Board, Chief Executive Officer
  • Thierry Moulin, Chief Financial Officer
  • Mathieu Simon, Chief Operating Officer, Executive Vice President, Director
  • David J.D. Sourdive, Executive Vice President-Corporate Development, Director
  • Philippe Duchateau, Chief Scientific Officer
  • Laurent Arthaud, Independent Director
  • Pierre Bastid, Independent Director
  • Alain Godard, Independent Director
  • Jean-Marie Messier, Independent Director
  • Annick Schwebig, Independent Director

When did Cellectis S.A. IPO?

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

Who owns Cellectis S.A. stock?

Cellectis S.A.'s stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (10.01%), Tekla Capital Management LLC (0.87%), Lazard Asset Management LLC (0.75%), Sphera Funds Management LTD. (0.58%), Artal Group S.A. (0.28%) and DAFNA Capital Management LLC (0.21%). View Institutional Ownership Trends for Cellectis S.A..

Who sold Cellectis S.A. stock? Who is selling Cellectis S.A. stock?

Cellectis S.A.'s stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Lazard Asset Management LLC and GAM Holding AG. View Insider Buying and Selling for Cellectis S.A..

Who bought Cellectis S.A. stock? Who is buying Cellectis S.A. stock?

Cellectis S.A.'s stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Balyasny Asset Management LLC, Williams Jones & Associates LLC, Wells Fargo & Company MN, FMR LLC, Eqis Capital Management Inc. and ARK Investment Management LLC. View Insider Buying and Selling for Cellectis S.A..

How do I buy Cellectis S.A. stock?

Shares of Cellectis S.A. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellectis S.A.'s stock price today?

One share of Cellectis S.A. stock can currently be purchased for approximately $27.92.


MarketBeat Community Rating for Cellectis S.A. (NASDAQ CLLS)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  227
MarketBeat's community ratings are surveys of what our community members think about Cellectis S.A. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cellectis S.A. (NASDAQ:CLLS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $40.00 (43.27% upside)

Analysts' Ratings History for Cellectis S.A. (NASDAQ:CLLS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/6/2017NomuraLower Price TargetBuy$49.00 -> $43.00LowView Rating Details
9/5/2017SunTrust Banks, Inc.DowngradeBuy -> Hold$35.00 -> $20.00HighView Rating Details
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform -> Outperform$33.00 -> $40.00HighView Rating Details
8/25/2017Jefferies Group LLCSet Price TargetBuy$47.00HighView Rating Details
6/3/2017Oppenheimer Holdings, Inc.Reiterated RatingBuyLowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$49.00N/AView Rating Details
11/24/2016Piper Jaffray CompaniesSet Price TargetBuy$41.00N/AView Rating Details
4/5/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$45.00N/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Cellectis S.A. (NASDAQ:CLLS)
Earnings by Quarter for Cellectis S.A. (NASDAQ:CLLS)
Earnings History by Quarter for Cellectis S.A. (NASDAQ CLLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/28/2017        
11/16/2015Q215($0.43)($0.40)$1.23 million$11.10 millionViewN/AView Earnings Details
9/8/2015Q2 2015($0.64)($0.70)$2.37 million$8.85 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cellectis S.A. (NASDAQ:CLLS)
2017 EPS Consensus Estimate: ($2.66)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.71)($0.65)($0.68)
Q2 20172($0.69)($0.60)($0.65)
Q3 20172($0.73)($0.54)($0.64)
Q4 20172($0.77)($0.63)($0.70)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cellectis S.A. (NASDAQ:CLLS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cellectis S.A. (NASDAQ:CLLS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Cellectis S.A. (NASDAQ:CLLS)
Latest Headlines for Cellectis S.A. (NASDAQ:CLLS)
Source:
DateHeadline
americanbankingnews.com logo$10.56 Million in Sales Expected for Cellectis S.A. (CLLS) This Quarter
www.americanbankingnews.com - September 15 at 3:40 AM
americanbankingnews.com logoZacks: Brokerages Expect Cellectis S.A. (CLLS) to Post -$0.57 Earnings Per Share
www.americanbankingnews.com - September 13 at 4:26 PM
finance.yahoo.com logoINVESTOR ALERT: Goldberg Law PC Announces an Investigation of Cellectis S.A.
finance.yahoo.com - September 8 at 5:38 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Cellectis S.A.
finance.yahoo.com - September 7 at 5:23 PM
marketwatch.com logoS&P 500 snaps 6-day win streak on policy uncertainty, North Korea tensions
www.marketwatch.com - September 6 at 5:15 PM
americanbankingnews.com logoNomura Lowers Cellectis SA (CLLS) Price Target to $43.00
www.americanbankingnews.com - September 6 at 3:20 PM
247wallst.com logoFDA Crushes Cellectis With Clinical Hold
247wallst.com - September 5 at 11:51 PM
benzinga.com logoMid-Day Market Update: Crude Oil Up Over 3%; Cellectis Shares Plummet - Benzinga
www.benzinga.com - September 5 at 6:51 PM
seekingalpha.com logoCellectis down 29% premarket on FDA hold on studies of UCART123 after fatality - Seeking Alpha
seekingalpha.com - September 5 at 6:51 PM
nasdaq.com logoPre-Market Most Active for Sep 5, 2017 : INSM, COL, TVIX, ING, DB, BAC, UTX, CLLS, TEVA, XIV, AAPL, QQQ - Nasdaq
www.nasdaq.com - September 5 at 6:51 PM
prnewswire.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis SA - CLLS - PR Newswire (press release)
www.prnewswire.com - September 5 at 6:50 PM
prnewswire.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Cellectis SA (CLLS) - PR Newswire (press release)
www.prnewswire.com - September 5 at 6:50 PM
finance.yahoo.com logoCellectis's stock plunges after leukemia treatment trials were put on hold
finance.yahoo.com - September 5 at 6:50 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
finance.yahoo.com - September 5 at 6:50 PM
finance.yahoo.com logoHere's​ ​Why Cellectis SA Fell as Much as 31.6% Today
finance.yahoo.com - September 5 at 6:50 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Cellectis S.A. (CLLS)
finance.yahoo.com - September 5 at 6:50 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Cellectis S.A.
finance.yahoo.com - September 5 at 6:50 PM
finance.yahoo.com logoWhy Mallinckrodt, Universal Insurance Holdings, and Cellectis Slumped Today
finance.yahoo.com - September 5 at 6:50 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Cellectis S.A.
finance.yahoo.com - September 5 at 6:50 PM
americanbankingnews.com logoCellectis' (CLLS) "Outperform" Rating Reaffirmed at Wells Fargo & Company
www.americanbankingnews.com - September 5 at 11:40 AM
americanbankingnews.com logoSunTrust Banks, Inc. Lowers Cellectis S.A. (CLLS) to Hold
www.americanbankingnews.com - September 5 at 11:06 AM
finance.yahoo.com logoCellectis Reports Clinical Hold of UCART123 Studies
finance.yahoo.com - September 5 at 3:16 AM
finance.yahoo.com logoCellectis to Participate in Upcoming Investor Conferences
finance.yahoo.com - September 5 at 3:16 AM
americanbankingnews.com logoCellectis S.A. (CLLS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 2 at 2:44 AM
marketwatch.com logoNovartis' CAR-T therapy was the first approved in US — here's how to invest in the space - MarketWatch
www.marketwatch.com - August 31 at 5:08 PM
forbes.com logoAfter Gilead's Acquisition Of KITE, Who Gets Gobbled Up Next? - Forbes
www.forbes.com - August 30 at 4:19 PM
nasdaq.com logoCellectis (CLLS) Catches Eye: Stock Jumps 17% - Nasdaq
www.nasdaq.com - August 30 at 3:42 AM
seekingalpha.com logoGilead And Kite Pharma: The Game-Changing Acquisition We Have Been Waiting For
seekingalpha.com - August 29 at 5:39 PM
finance.yahoo.com logoCellectis (CLLS) Catches Eye: Stock Jumps 17%
finance.yahoo.com - August 29 at 5:39 PM
americanbankingnews.com logoBidaskClub Upgrades Cellectis S.A. (CLLS) to Sell
www.americanbankingnews.com - August 28 at 10:32 PM
marketwatch.com logoBiotech stocks surge on Gilead's Kite Pharma acquisition - MarketWatch
www.marketwatch.com - August 28 at 10:11 PM
americanbankingnews.com logoJefferies Group LLC Reiterates $47.00 Price Target for Cellectis S.A. (CLLS)
www.americanbankingnews.com - August 26 at 11:02 AM
americanbankingnews.com logoQ3 2017 Earnings Estimate for Cellectis S.A. Issued By Oppenheimer Holdings (CLLS)
www.americanbankingnews.com - August 21 at 3:40 AM
finance.yahoo.com logoCellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center
finance.yahoo.com - August 17 at 6:33 PM
americanbankingnews.com logoCellectis S.A. (NASDAQ:CLLS) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 10 at 8:28 PM
americanbankingnews.com logoCellectis S.A. (NASDAQ:CLLS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 8 at 7:32 AM
americanbankingnews.com logo Analysts Expect Cellectis S.A. (NASDAQ:CLLS) to Announce -$0.61 EPS
www.americanbankingnews.com - August 7 at 6:20 PM
businesswire.com logoCellectis Reports Financial Results for 2 - Business Wire (press release)
www.businesswire.com - August 3 at 4:05 AM
finance.yahoo.com logoCellectis Reports Financial Results for 2nd Quarter and First Six Months 2017
finance.yahoo.com - August 2 at 6:04 PM
businesswire.com logoCellectis S.A.: Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering
www.businesswire.com - July 27 at 3:35 AM
businesswire.com logoCalyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering - Business Wire (press release)
www.businesswire.com - July 25 at 10:15 PM
businesswire.com logoCellectis SA: Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering - Business Wire (press release)
www.businesswire.com - July 25 at 5:13 PM
seekingalpha.com logoBiotech Bonanza: The Next Leg Up - Seeking Alpha
seekingalpha.com - July 25 at 5:12 PM
finance.yahoo.com logoCellectis S.A.: Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering
finance.yahoo.com - July 25 at 5:12 PM
finance.yahoo.com logoCellectis Granted Patent for CRISPR Use in T-Cells
finance.yahoo.com - July 24 at 4:51 PM
thestreet.com logoGene Editing Company Joins NASDAQ, Jumps Over 20% on First ... - TheStreet.com
www.thestreet.com - July 22 at 4:51 AM
nasdaq.com logoNew Strong Buy Stocks for July 20th - Nasdaq
www.nasdaq.com - July 21 at 12:08 AM
americanbankingnews.com logoCellectis S.A. (CLLS) Expected to Announce Quarterly Sales of $10.30 Million
www.americanbankingnews.com - July 20 at 11:44 AM
finance.yahoo.com logoCellectis S.A.: Calyxt Announces Pricing of $56.0 Million Initial Public Offering
finance.yahoo.com - July 19 at 11:28 PM
americanbankingnews.com logoCellectis S.A. (NASDAQ:CLLS) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - July 19 at 9:50 PM

Social

Chart

Cellectis S.A. (CLLS) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff